James A. Gow

703 total citations
37 papers, 464 citations indexed

About

James A. Gow is a scholar working on Ophthalmology, Public Health, Environmental and Occupational Health and Immunology and Allergy. According to data from OpenAlex, James A. Gow has authored 37 papers receiving a total of 464 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Ophthalmology, 14 papers in Public Health, Environmental and Occupational Health and 10 papers in Immunology and Allergy. Recurrent topics in James A. Gow's work include Glaucoma and retinal disorders (16 papers), Ocular Surface and Contact Lens (14 papers) and Allergic Rhinitis and Sensitization (10 papers). James A. Gow is often cited by papers focused on Glaucoma and retinal disorders (16 papers), Ocular Surface and Contact Lens (14 papers) and Allergic Rhinitis and Sensitization (10 papers). James A. Gow collaborates with scholars based in United States, United Kingdom and Germany. James A. Gow's co-authors include Jon I. Williams, Lisa R. Grillone, Eric D. Donnenfeld, Robert H. Stewart, Edward J. Holland, Paul J Gomes, Mark B. Abelson, Gail Torkildsen, James H. Peace and Thomas R. Walters and has published in prestigious journals such as JAMA, Nature Medicine and Journal of Allergy and Clinical Immunology.

In The Last Decade

James A. Gow

37 papers receiving 413 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James A. Gow United States	13	291	154	118	90	60	37	464
Reza Haque United States	7	169 0.6×	228 1.5×	78 0.7×	20 0.2×	101 1.7×	11	346
Eugene McLaurin United States	13	345 1.2×	483 3.1×	229 1.9×	28 0.3×	149 2.5×	36	698
Gregg J. Berdy United States	17	282 1.0×	499 3.2×	242 2.1×	43 0.5×	242 4.0×	34	731
Hiroki Urashima Japan	8	146 0.5×	281 1.8×	39 0.3×	10 0.1×	101 1.7×	13	364
Xiaolei Lin China	15	293 1.0×	300 1.9×	59 0.5×	11 0.1×	221 3.7×	33	574
Delmar R. Caldwell United States	14	341 1.2×	199 1.3×	36 0.3×	46 0.5×	287 4.8×	27	583
L. Motterle Italy	8	147 0.5×	394 2.6×	219 1.9×	10 0.1×	153 2.5×	9	472
Archana Padmanabhan Nair India	11	118 0.4×	213 1.4×	27 0.2×	10 0.1×	142 2.4×	28	334
Kenneth A. Beckman United States	11	171 0.6×	240 1.6×	47 0.4×	8 0.1×	177 3.0×	19	406
John Lonsdale United States	5	119 0.4×	357 2.3×	180 1.5×	7 0.1×	93 1.6×	5	394

Countries citing papers authored by James A. Gow

Since Specialization

Citations

This map shows the geographic impact of James A. Gow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James A. Gow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James A. Gow more than expected).

Fields of papers citing papers by James A. Gow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James A. Gow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James A. Gow. The network helps show where James A. Gow may publish in the future.

Co-authorship network of co-authors of James A. Gow

This figure shows the co-authorship network connecting the top 25 collaborators of James A. Gow. A scholar is included among the top collaborators of James A. Gow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James A. Gow. James A. Gow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

MacLaren, Robert E., Jacque L. Duncan, M. Dominik Fischer, et al.. (2024). XOLARIS: A 24-Month, Prospective, Natural History Study of 201 Participants with Retinitis Pigmentosa GTPase Regulator-Associated X-Linked Retinitis Pigmentosa. Ophthalmology Science. 5(1). 100595–100595. 3 indexed citations

MacLaren, Robert E., Byron L. Lam, Manuel Fischer, et al.. (2024). A Prospective, Observational, Non-interventional Clinical Study of Participants With Choroideremia: The NIGHT Study. American Journal of Ophthalmology. 263. 35–49. 4 indexed citations

MacLaren, Robert E., Isabelle Audo, Manuel Fischer, et al.. (2024). An Open-Label Phase II Study Assessing the Safety of Bilateral, Sequential Administration of Retinal Gene Therapy in Participants with Choroideremia: The GEMINI Study. Human Gene Therapy. 35(15-16). 564–575. 5 indexed citations

MacLaren, Robert E., Manuel Fischer, James A. Gow, et al.. (2023). Subretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trial. Nature Medicine. 29(10). 2464–2472. 31 indexed citations

Walters, Thomas R., Damien F. Goldberg, James H. Peace, & James A. Gow. (2013). Bromfenac Ophthalmic Solution 0.07% Dosed Once Daily for Cataract Surgery. Ophthalmology. 121(1). 25–33. 35 indexed citations

Torkildsen, Gail, et al.. (2012). Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis. Allergy and Asthma Proceedings. 33(3). 265–274. 8 indexed citations

Williams, Jon I., et al.. (2011). Prolonged Effectiveness of Bepotastine Besilate Ophthalmic Solution for the Treatment of Ocular Symptoms of Allergic Conjunctivitis. Journal of Ocular Pharmacology and Therapeutics. 27(4). 385–393. 14 indexed citations

Henderson, Bonnie An, et al.. (2011). Safety and Efficacy of Bromfenac Ophthalmic Solution (Bromday) Dosed Once Daily for Postoperative Ocular Inflammation and Pain. Ophthalmology. 118(11). 2120–2127. 30 indexed citations

Williams, Jon I., et al.. (2010). Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilate. Current Medical Research and Opinion. 26(10). 2329–2338. 22 indexed citations

10.

Williams, Jon I., et al.. (2010). Multicenter Clinical Evaluation of Bepotastine Besilate Ophthalmic Solutions 1.0% and 1.5% to Treat Allergic Conjunctivitis. American Journal of Ophthalmology. 150(1). 122–127.e5. 18 indexed citations

11.

Torkildsen, Gail, et al.. (2010). Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge. Annals of Allergy Asthma & Immunology. 105(1). 57–64. 15 indexed citations

12.

McLaurin, Eugene, et al.. (2009). Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Tearing at 8 Hours Following Dosing in a Multi-Site Clinical Trial Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis. Investigative Ophthalmology & Visual Science. 50(13). 6324–6324. 1 indexed citations

13.

Abelson, Mark B., et al.. (2009). Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: A phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children. Clinical Therapeutics. 31(9). 1908–1921. 32 indexed citations

14.

Torkildsen, Gail, et al.. (2009). Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Ocular Itching in a Clinical Model of Allergic Conjunctivitis. Journal of Allergy and Clinical Immunology. 123(2). S57–S57. 3 indexed citations

15.

Miyake, Kensaku, et al.. (2008). Ocular Pharmacokinetics of a Single Dose of Bromfenac Sodium Ophthalmic Solution 0.1% in Human Aqueous Humor. Journal of Ocular Pharmacology and Therapeutics. 24(6). 573–578. 21 indexed citations

16.

Gow, James A., et al.. (2008). 24-Hour Evaluation of the Ocular Distribution of ¹⁴ C-Labeled Bromfenac Following Topical Instillation into the Eyes of New Zealand White Rabbits. Journal of Ocular Pharmacology and Therapeutics. 24(4). 392–398. 41 indexed citations

17.

Bhavsar, Abdhish R., et al.. (2008). Predicting Response of Vitreous Hemorrhage after Intravitreous Injection of Highly Purified Ovine Hyaluronidase (Vitrase) in Patients with Diabetes. Investigative Ophthalmology & Visual Science. 49(10). 4219–4219. 7 indexed citations

18.

Donnenfeld, Eric D., Edward J. Holland, Robert H. Stewart, James A. Gow, & Lisa R. Grillone. (2007). Bromfenac Ophthalmic Solution 0.09% (Xibrom) for Postoperative Ocular Pain and Inflammation. Ophthalmology. 114(9). 1653–1662.e1. 70 indexed citations

19.

Gow, James A., et al.. (2006). Concentrations of Radioactivity in Ocular Tissues Following a Single Topical Ocular Dose of 14C–Bromfenac Ophthalmic Solution (XibromTM). 47(13). 5086–5086. 2 indexed citations

20.

Gow, James A.. (1974). Inclusive Conjunctivitis With Hearing Loss. JAMA. 229(5). 519–519. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact